Pfizer inks peptide deal with Sutro

Sutro Biopharma has landed a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics. Financial details of the deal were not disclosed. The company says it's developing new and biosuperior protein therapeutics with better pharmaceutical properties. Sutro recently raised. $36.5 million in a Series C financing. Sutro release

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.